923604-58-4 ((2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸,(1S,4R,6R,15S)-17-[7-Methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid)

CAS号:
923604-58-4
中文名称:
(2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸
英文名称:
(1S,4R,6R,15S)-17-[7-Methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid
分子式:
C35H42N4O6S
分子量:
646.796187877655

(2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸(923604-58-4)名称与标识符

名称

中文别名:
(2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸;Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro;
英文别名:
(2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸;Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]o;(1S,4R,6R,15S)-17-[7-Methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-;(1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid;(2R,3aR,11aS,12aR,14aR,Z)-2-((2-(4-Isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxylic acid;SCHEMBL826164;CS-M1877;923604-58-4;(2R,3aR,11aS,12aR,14aR,Z)-2-((2-(4-Isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxylicacid;AS-75347;Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)-;(1R,4R,6S,7Z,15R,17R)-17-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0?,?]octadec-7-ene-4-carboxylic acid;AKOS030568007;(2R,3aR,10Z,11aS,12aR,14aR)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-Tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid;618-844-9;(2R,3aR,10Z,11aS,12aR,14aR)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-Tetradecahydro-2-((7-methoxy-8-methyl-2-(4-(1-methylethyl)-2-thiazolyl)-4-quinolinyl)oxy)-5-methyl-4,14-dioxocyclopenta(c)cyclopropa(g)(1,6)diazacyclotetradecine-12a(1H)-carboxylic acid;cyclopenta(c)cyclopropa(g)(1,6)diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-((7-methoxy-8-methyl-2-(4-(1-methylethyl)-2-thiazolyl)-4-quinolinyl)oxy)-5-methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)-;

标识符

MDL:
MFCD22665924
InChIKey:
XQOBFRSIHBMNMC-PLGQPLIWSA-N
Inchi:
1S/C35H42N4O6S/c1-19(2)27-18-46-32(37-27)26-16-29(23-11-12-28(44-5)20(3)30(23)36-26)45-22-14-24-25(15-22)33(41)39(4)13-9-7-6-8-10-21-17-35(21,34(42)43)38-31(24)40/h8,10-12,16,18-19,21-22,24-25H,6-7,9,13-15,17H2,1-5H3,(H,38,40)(H,42,43)/b10-8-/t21-,22-,24-,25-,35-/m1/s1
SMILES:
S1C=C(C(C)C)N=C1C1=CC(=C2C=CC(=C(C)C2=N1)OC)O[C@H]1C[C@H]2C(N(C)CCCCC=C[C@@H]3C[C@@]3(C(=O)O)NC([C@@H]2C1)=O)=O |c:35|

(2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸(923604-58-4)物化性质

计算特性

  • 精确分子量 : 646.28250625g/mol
  • 氢键供体数量 : 2
  • 氢键受体数量 : 9
  • 可旋转化学键数量 : 6
  • 同位素质量 : 646.28250625g/mol
  • 重原子数量 : 46
  • 复杂度 : 1170
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 5
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 1
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 4.9
  • 拓扑分子极性表面积 : 159

(2R,3AR,11AS,12AR,14AR,Z)-2-(2-(4-异丙基噻唑-2-基)-7-甲氧基-8-甲基-4-喹啉氧基)-5-甲基-4,14-二氧-1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A-16氢环戊烷并[C]环丙基并[G][1,6]双氮杂十四烷-12A-羧酸(923604-58-4)推荐厂家 更多厂家(7)